Editorially independent · We do not sell peptides
§ GLOSSARY

Glossary

Plain-language definitions for the classifications, badges, and jargon used across the encyclopedia.

  1. 503A compounding Regulatory
    503A pharmacy · 503A compounder

    A U.S. regulatory category permitting state-licensed pharmacies to compound customized medications for individual patients on the basis of a valid prescription.

  2. Agonist Pharmacology

    A molecule that binds to a receptor and activates it, producing a biological response.

  3. Amino acid Peptide chemistry
    AA · residue

    The molecular building block of peptides and proteins, consisting of an amino group, a carboxyl group, and a variable side chain.

  4. Antagonist Pharmacology

    A molecule that binds to a receptor without activating it, blocking the receptor from being activated by its natural agonist.

  5. AUC Pharmacokinetics
    area under the curve · AUC₀₋∞ · exposure

    Area Under the Curve — total drug exposure over time, calculated by integrating the plasma-concentration-versus-time curve.

  6. Bacteriostatic water Peptide chemistry
    BAC water · BAC

    Sterile water containing 0.9% benzyl alcohol as a preservative, used to reconstitute lyophilized peptides for multi-dose use.

  7. Bioavailability Pharmacokinetics
    F · F%

    The fraction of an administered dose that reaches systemic circulation in unchanged form.

  8. Clearance Pharmacokinetics
    CL · total clearance

    The volume of plasma cleared of a substance per unit time, typically expressed in mL/min or L/h.

  9. Cmax Pharmacokinetics
    peak concentration · C-max

    The maximum plasma concentration of a drug after administration.

  10. Contraindication Interaction

    A specific situation in which a drug or procedure should not be used because it may harm the patient.

  11. Double-blind Research
    double-masked

    A trial design in which neither participants nor investigators know who is receiving the intervention or the control.

  12. EMA Regulatory
    European Medicines Agency

    European Medicines Agency — the EU regulator responsible for the centralized authorisation procedure for medicines.

  13. FDA Regulatory
    U.S. Food and Drug Administration · Food and Drug Administration

    U.S. Food and Drug Administration — the U.S. regulator for food, drugs, biologics, devices, and cosmetics.

  14. GHRH analog Compound class
    growth-hormone-releasing hormone analog

    A synthetic peptide structurally similar to growth-hormone-releasing hormone, used to stimulate endogenous growth-hormone secretion.

  15. GLP-1 agonist Compound class
    GLP-1 RA · GLP-1 receptor agonist

    A drug that activates the GLP-1 receptor, increasing insulin secretion and slowing gastric emptying.

  16. Half-life Pharmacokinetics
    t½ · t1/2 · elimination half-life

    The time required for the plasma concentration of a substance to decrease by half.

  17. INN Regulatory
    International Nonproprietary Name · generic name

    International Nonproprietary Name — the unique generic name assigned to a pharmaceutical substance by the WHO.

  18. Intramuscular Administration route
    IM · i.m.

    Injection directly into muscle tissue, typically in the deltoid, vastus lateralis, or gluteus.

  19. Lyophilized Peptide chemistry
    freeze-dried · lyo

    Freeze-dried into a stable powder by sublimation under vacuum after freezing in solution.

  20. MACE Clinical trial
    3-point MACE · 4-point MACE

    Major Adverse Cardiovascular Events — a composite endpoint typically combining cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke.

  21. Mechanism of action Pharmacology
    MoA · MOA · mode of action

    The molecular pathway by which a drug produces its therapeutic effect.

  22. Melanocortin agonist Compound class
    MC agonist · melanocortin receptor agonist

    A drug that activates one or more melanocortin receptors (MC1R–MC5R), with effects on pigmentation, energy balance, and sexual function.

  23. Nasal Administration route
    intranasal

    Administration via the nasal mucosa, typically as a spray.

  24. Oral Administration route
    per os · PO

    Administration by mouth, with absorption through the gastrointestinal tract.

  25. Peer review Research
    refereeing

    Independent evaluation of a manuscript by domain experts before journal publication.

  26. Peptide Peptide chemistry
    polypeptide

    A short chain of amino acids linked by peptide bonds, typically containing between 2 and 50 residues.

  27. Phase 3 Clinical trial
    phase III · Phase III

    A large-scale clinical trial designed to confirm efficacy and monitor adverse events in the target population, typically the last step before regulatory submission.

  28. Placebo Research
    sham · vehicle

    An inert intervention given to a control group to isolate the specific effect of the active intervention.

  29. Prescription-only Regulatory
    POM · Rx-only · prescription medicine

    A regulatory status requiring a valid prescription from a licensed healthcare provider before dispensing.

  30. Primary endpoint Clinical trial
    primary outcome · PO

    The principal outcome measure used to evaluate whether a clinical trial succeeded or failed.

  31. RCT Research
    randomized controlled trial · randomised controlled trial

    Randomized Controlled Trial — a study design that randomly assigns participants to intervention or control groups to minimize bias.

  32. Receptor Pharmacology

    A protein on a cell that binds a specific signaling molecule and triggers a cellular response.

  33. Sample size Research
    n · study size

    The number of participants in a study, denoted n.

  34. Secretagogue Pharmacology

    A substance that causes another substance to be secreted from a tissue or gland.

  35. Subcutaneous Administration route
    SC · s.c. · subQ

    Injection into the fatty tissue just beneath the skin, typically in the abdomen, thigh, or upper arm.

  36. Synergistic Interaction
    potentiation

    Producing a combined effect greater than the sum of the individual effects.

  37. Topical Administration route
    cutaneous

    Application to the skin or mucous membrane, with the active ingredient acting locally or absorbing into nearby tissue.